| name | Autologous Stem Cell Therapy |
| classification | | 1 | Regenerative Medicine | | 2 | Cellular Therapy |
|
| pharmacokinetics | Not applicable in the traditional sense. The pharmacokinetic considerations relate to the process of mobilization, collection, processing, and reinfusion of the patient's own stem cells. No drug is absorbed, distributed, metabolized, or excreted in the conventional drug context. |
| suggested dosage | Highly individualized and not standardized. Determined by the specific disease, patient's health, and stem cell type. Precise protocols are developed for each individual case and stem cell collection. |
| indications | | 1 | Hematological malignancies (e.g., leukemia, lymphoma) | | 2 | Solid tumors (e.g., breast cancer, melanoma) | | 3 | Autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis) | | 4 | Ischemic heart disease | | 5 | Stroke | | 6 | Diabetic nephropathy | | 7 | Neurodegenerative diseases (e.g., Parkinson's disease) | | 8 | Certain types of spinal cord injury | | 9 | Severe burns |
|
| safety in pregnancy | Not recommended. Pregnant women or those planning pregnancy should discuss risks and benefits with a specialist. Limited data exists on safety in pregnancy. |
| safety in breastfeeding | Not recommended due to potential risk to the infant. Consult a medical specialist for advice. |
| side effects | | 1 | Nausea | | 2 | Vomiting | | 3 | Fever | | 4 | Chills | | 5 | Fatigue | | 6 | Bone pain | | 7 | Muscle pain | | 8 | Headache | | 9 | Injection site redness/swelling | | 10 | Infection (immunosuppression) | | 11 | Thrombosis (blood clots) | | 12 | Reactions to anesthesia/medications | | 13 | Low-level immune suppression (especially with chemotherapy) |
|
| alternatives | |
| contraindications | | 1 | Active/uncontrolled infections | | 2 | Unstable medical conditions | | 3 | Certain blood clotting disorders | | 4 | Severe organ dysfunction | | 5 | Severe bleeding/clotting disorders |
|
| interactions | Interactions are complex. The process and potential side effects might interact with other medical treatments or conditions. Consult the treating physician about concurrent medications. |
| warnings and precautions | | 1 | Individualized risk assessment and treatment protocols are essential. | | 2 | Long-term side effects are not fully understood. | | 3 | Pre-existing conditions and certain treatments increase complication risk. | | 4 | Not a cure-all; may not be successful in all cases. |
|
| additional information | | 1 | Multidisciplinary approach (hematologists, oncologists, etc.) is common. | | 2 | Success varies widely based on disease, patient health, and stem cell type. | | 3 | Cost can be substantial and may not be fully covered by insurance. | | 4 | Treatment is a lengthy process (months). | | 5 | Patient age and weight are secondary factors to disease and overall patient condition in determining dosage. |
|
| patient profile | |
